Fortrea Holdings (FRA:K67) FCF Margin % : -5.27% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Fortrea Holdings FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Fortrea Holdings's Free Cash Flow for the three months ended in Mar. 2024 was €-32 Mil. Fortrea Holdings's Revenue for the three months ended in Mar. 2024 was €609 Mil. Therefore, Fortrea Holdings's FCF Margin % for the quarter that ended in Mar. 2024 was -5.27%.

As of today, Fortrea Holdings's current FCF Yield % is 4.45%.

The historical rank and industry rank for Fortrea Holdings's FCF Margin % or its related term are showing as below:

FRA:K67' s FCF Margin % Range Over the Past 10 Years
Min: 1.07 Med: 4.39 Max: 6.86
Current: 3.49

During the past 4 years, the highest FCF Margin % of Fortrea Holdings was 6.86%. The lowest was 1.07%. And the median was 4.39%.

FRA:K67's FCF Margin % is ranked better than
82.01% of 1045 companies
in the Biotechnology industry
Industry Median: -143.92 vs FRA:K67: 3.49

Fortrea Holdings FCF Margin % Historical Data

The historical data trend for Fortrea Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortrea Holdings FCF Margin % Chart

Fortrea Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Margin %

6.86

4.69

1.07

4.09

Fortrea Holdings Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial						-1.67	17.81	-0.55	0.39	-5.27

Competitive Comparison of Fortrea Holdings's FCF Margin %

For the Biotechnology subindustry, Fortrea Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fortrea Holdings's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortrea Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Fortrea Holdings's FCF Margin % falls into.

Fortrea Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Fortrea Holdings's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	116.551	/	2850.953
	=	4.09 %

Fortrea Holdings's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-32.108	/	609.132
	=	-5.27 %

Fortrea Holdings FCF Margin % Related Terms

Thank you for viewing the detailed overview of Fortrea Holdings's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Fortrea Holdings (FRA:K67) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (FRA:K67) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

FTRE:USA

Address

8 Moore Drive, Durham, NC, USA, 27709

Website

https://www.fortrea.com

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Fortrea Holdings (FRA:K67) Headlines

No Headlines